Stockreport

Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference [Yahoo! Finance]

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com
PDF its bempedoic acid therapies multiple Class 1A recommendations , which management expects will validate NEXLETOL/NEXLIZET positioning and expand the combination lipid-lo [Read more]